

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 6 of 24

EMR 200125-002

Confidential

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	AUC(0-48) (hr*ng/mL)	AUC(0-48,adj) (hr*ng/mL)	tmax (hr)	AUCextra,adj (hr*ng/mL)#
n(missing)	37 (0)	37 (0)	37 (0)	
Mean(SD)	4684.78 (455.288)	1673.84 (354.508)		
GeoMean	4663.35	1635.22		
(95% CI)	(4514.83;4816.75)	(1517.67;1761.87)		
GeoCV(CV%)	9.7 (9.7)	22.7 (21.2)		
SEM	74.849	58.281		
Median	4685.97	1719.50	2.500	
Min; Max	3938.0; 5585.3	933.3; 2527.4	1.00; 36.52	

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_Z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table

15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 7 of 24
Confidential

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment A

Subject Number/ Random Number	AUC0-∞, adj (hr*ng/mL)#	t1/2 (hr) #	λz (1/hr)^	Vz/F (L)#	CL/F (L/hr)#
	NE	NE	0.011	NE	NE
	NE	NE	0.012	NE	NE
	NE	NE	0.017	NE	NE
	NE	NE	0.009	NE	NE
	NE	NE	0.008	NE	NE
	NE	NE	0.006	NE	NE
	NE	NE	0.003	NE	NE
	NE	NE	0.013	NE	NE
	NE	NE	0.016	NE	NE
	NE	NE	0.002	NE	NE
	NE	NE	0.002	NE	NE
	NE	NE	0.007	NE	NE
	NE	NE	0.007	NE	NE
	NE	NE	0.011	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.014	NE	NE
	NE	NE	0.008	NE	NE
	NE	NE	0.014	NE	NE
	NE	NE	0.033	NE	NE

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 8 of 24

EMR 200125-002

Confidential

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	AUC _{0-∞, adj} (hr*ng/mL)#	t _{1/2} (hr)#	λ _z (1/hr)^	V _z /F (L)#	CL/F (L/hr)#
	NE	NE	0.008	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.005	NE	NE
	NE	NE	0.012	NE	NE
	NE	NE	0.016	NE	NE
	NE	NE	0.013	NE	NE
	NE	NE	0.006	NE	NE
	NE	NE	0.009	NE	NE
	NE	NE	0.009	NE	NE
	NE	NE	0.008	NE	NE
	NE	NE	0.010	NE	NE
	NE	NE	0.022	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.005	NE	NE
	NE	NE	0.007	NE	NE
	NE	NE	0.018	NE	NE
	NE	NE	0.014	NE	NE

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_z, All Lambda_z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 9 of 24

EMR 200125-002

Confidential

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters

(Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	AUC0-72 (hr*ng/mL)	AUC0-72, adj (hr*ng/mL)	Cmax (ng/mL)	Cmax, adj (ng/mL)
	6573.7*	2750.7*	133.10	80.003
	8071.7*	3023.3*	160.70	90.583
	7172.4*	2442.9*	125.70	60.013
	7717.5*	3417.9*	141.50	81.783
	7143.1	2324.9	135.00	68.080
	5702.4*	1993.7*	101.20	49.690
	6492.5*	2639.8*	125.90	72.390
	6550.2	1754.0	110.90	44.287
	6322.8*	2143.7*	103.70	45.657
	7342.0*	2756.5*	123.50	59.813
	8083.6*	3796.0*	158.90	99.350
	8455.1	3185.6	140.10	66.913
	8021.7	2722.0	158.90	85.293
	6317.2*	2960.0*	109.80	63.173
	5769.5	1213.1	108.50	45.217
	6300.2	2067.1	109.20	50.407
	7267.1	2267.6	134.30	64.863
	6010.4*	1384.4*	109.40	45.150
	6602.4*	2549.0*	107.10	50.803
	5637.0*	1790.5*	126.80	73.377

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table

15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 10 of 24
ConfidentialTable 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment B

Subject Number/ Random Number	AUC0-72 (hr*ng/mL)	AUC0-72, adj (hr*ng/mL)	Cmax (ng/mL)	Cmax, adj (ng/mL)
	5601.4*	1056.8*	107.60	44.480
	7613.9*	2722.2*	124.40	56.460
	7426.6*	3288.2*	122.00	64.523
	6583.2	1703.8	127.30	59.530
	5847.6*	2187.6*	111.00	60.167
	7985.4	2532.1	161.50	85.760
	6141.2	2210.0	113.70	59.100
	6547.5*	2102.9*	110.40	48.670
	6999.5*	1812.6*	128.60	56.560
	7287.4*	2783.3*	122.50	59.943
	6031.9*	2240.6*	108.00	55.343
	6951.1	2351.0	126.20	62.310
	8072.1	2816.8	152.80	79.810
	5737.0*	1250.5*	107.80	45.487
	7207.1*	1740.6*	144.40	68.477
	7855.4	2913.8	147.20	78.567
	5893.7	1430.4	136.50	74.510

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_Z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 11 of 24
ConfidentialTable 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment B

Subject Number/ Random Number	AUC0-72 (hr*ng/mL)	AUC0-72,adj (hr*ng/mL)	Cmax (ng/mL)	Cmax,adj (ng/mL)
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	6846.87 (838.557)	2333.14 (649.583)	126.381 (17.7666)	63.6903 (14.41836)
GeoMean (95% CI)	6797.17 (6525.39;7080.26)	2237.16 (2021.46;2475.88)	125.208 (119.599;131.081)	62.1576 (57.7031;66.9560)
GeoCV(CV%)	12.3 (12.2)	31.1 (27.8)	13.8 (14.1)	22.6 (22.6)
SEM	137.858	106.791	2.9208	2.37036
Median	6602.39	2324.91	125.700	60.1670
Min; Max	5601.4; 8455.1	1056.8; 3796.0	101.20; 161.50	44.287; 99.350

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 12 of 24

EMR 200125-002

Confidential

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	AUC(0-48) (hr*ng/mL)	AUC(0-48,adj) (hr*ng/mL)	tmax (hr)	AUCextra,adj (hr*ng/mL)#
	4556.8	2008.1	2.00	NE
	5636.1	2270.5	3.02	NE
	4939.7	1786.7	2.50	NE
	5306.3	2439.9	2.50	NE
	4872.1	1659.9	1.50	NE
	4073.5	1601.1	6.00	NE
	4349.2	1780.7	4.00	NE
	4635.1	1437.6	10.00	NE
	4368.9	1582.8	3.00	NE
	5226.9	2169.9	24.08	NE
	5757.6	2899.2	2.50	NE
	5647.5	2134.5	6.02	NE
	5380.7	1847.5	1.50	NE
	4317.3	2079.2	1.00	NE
	3962.1	924.5	4.00	NE
	4122.1	1300.0	10.03	NE
	4951.4	1618.4	2.50	NE
	4111.9	1027.9	4.02	NE
	4478.7	1776.4	1.50	NE
	3862.6	1298.3	2.02	NE

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_Z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 13 of 24

EMR 200125-002

Confidential

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	AUC(0-48) (hr*ng/mL)	AUC(0-48,adj) (hr*ng/mL)	tmax (hr)	AUCextra,adj (hr*ng/mL)#
	3855.4	825.6	1.50	NE
	5074.9	1813.8	12.00	NE
	5075.2	2316.3	12.02	NE
	4535.4	1282.4	2.52	NE
	4064.9	1625.0	2.02	NE
	5620.3	1984.8	2.50	NE
	4226.9	1606.1	2.50	NE
	4626.8	1663.8	2.02	NE
	4824.0	1366.1	1.50	NE
	4946.5	1943.8	4.02	NE
	4129.1	1601.6	2.50	NE
	4766.6	1699.9	2.50	NE
	5444.6	1941.1	1.50	NE
	3911.5	920.5	1.50	NE
	5063.6	1419.3	1.50	NE
	5338.8	2044.4	1.50	NE
	4130.4	1154.9	1.50	NE

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_Z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 14 of 24
ConfidentialTable 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment B

Subject Number/ Random Number	AUC(0-48) (hr*ng/mL)	AUC(0-48,adj) (hr*ng/mL)	tmax (hr)	AUCextra,adj (hr*ng/mL)#
n(missing)	37 (0)	37 (0)	37 (0)	
Mean(SD)	4707.87 (574.186)	1698.72 (448.630)		
GeoMean (95% CI)	4674.01 (4488.05;4867.68)	1637.71 (1490.82;1799.07)		
GeoCV(CV%)	12.2 (12.2)	28.8 (26.4)		
SEM	94.396	73.754		
Median	4635.06	1663.78	2.500	
Min; Max	3855.4; 5757.6	825.6; 2899.2	1.00; 24.08	

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_Z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table

15.4.1.1.2.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 15 of 24
ConfidentialTable 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment B

Subject Number/ Random Number	AUC _{0-∞} , adj (hr*ng/mL)#	t _{1/2} (hr)#	λ _z (1/hr)^	V _z /F (L)#	CL/F (L/hr)#
	NE	NE	0.006	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.008	NE	NE
	NE	NE	0.012	NE	NE
	NE	NE	0.009	NE	NE
	NE	NE	0.033	NE	NE
	NE	NE	0.003	NE	NE
	NE	NE	0.038	NE	NE
	NE	NE	0.017	NE	NE
	NE	NE	0.024	NE	NE
	NE	NE	0.014	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.009	NE	NE
	NE	NE	0.002	NE	NE
	NE	NE	0.012	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.007	NE	NE
	NE	NE	0.023	NE	NE
	NE	NE	0.006	NE	NE
	NE	NE	NE	NE	NE

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_z, All Lambda_z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 16 of 24

EMR 200125-002

Confidential

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	AUC _{0-∞} , adj (hr*ng/mL)#	t _{1/2} (hr)#	λ _z (1/hr)^	V _z /F (L)#	CL/F (L/hr)#
	NE	NE	0.025	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.008	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.020	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.013	NE	NE
	NE	NE	0.027	NE	NE
	NE	NE	0.009	NE	NE
	NE	NE	0.015	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.008	NE	NE
	NE	NE	0.009	NE	NE
	NE	NE	0.012	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.006	NE	NE
	NE	NE	0.038	NE	NE

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 17 of 24
ConfidentialTable 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment C

Subject Number/ Random Number	AUC0-72 (hr*ng/mL)	AUC0-72,adj (hr*ng/mL)	Cmax (ng/mL)	Cmax,adj (ng/mL)
	6793.7	2187.7	117.30	53.327
	7267.5*	2764.2*	136.00	73.453
	7124.3	2288.3	120.30	53.133
	7309.5	2234.9	126.30	55.820
	7944.8	2673.9	144.30	71.093
	6165.7	2201.9	105.10	50.047
	6575.9	2777.7	107.40	54.647
	6521.0	1933.1	128.00	64.280
	6856.0*	2144.8*	113.10	47.667
	6706.4*	1928.7*	127.50	61.143
	8274.1	3954.6	145.50	85.507
	7538.9	2840.4	120.20	54.943
	8232.9*	2412.4*	141.80	60.960
	6506.5*	2813.6*	114.40	63.110
	6131.1	1718.8	115.00	53.717
	6954.5*	2536.6*	126.20	64.840
	7573.8	2201.6	128.20	53.587
	6089.3	1963.2	102.60	45.293
	6818.8*	2776.0*	108.00	51.850
	5657.4*	2340.6*	104.50	58.433

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.
^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 18 of 24

EMR 200125-002

Confidential

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	AUC ₀₋₇₂ (hr*ng/mL)	AUC _{0-72, adj} (hr*ng/mL)	C _{max} (ng/mL)	C _{max, adj} (ng/mL)
	6153.9	1550.9	120.90	56.970
	6636.4*	2586.2*	140.70	84.447
	7451.4*	3528.6*	138.10	83.617
	7318.3	2623.2	152.50	87.290
	6941.4*	2563.1*	112.40	51.590
	7445.5	2014.7	138.30	62.873
	6324.2	2313.6	104.10	48.397
	7115.7*	2549.7*	116.30	52.883
	6507.9*	1594.4*	114.90	46.657
	6167.1*	2159.0*	116.30	60.633
	5927.2	2452.3	114.70	66.437
	7367.5	2035.4	145.50	71.443
	8289.1*	3340.0*	148.40	79.663
	6995.6*	2335.1*	129.50	64.770
	7063.3	1877.1	144.10	72.070
	8098.7	2567.5	148.60	71.777
	5855.2	1528.9	146.50	86.413

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_Z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 19 of 24

EMR 200125-002

Confidential

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	AUC0-72 (hr*ng/mL)	AUC0-72, adj (hr*ng/mL)	Cmax (ng/mL)	Cmax, adj (ng/mL)
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean (SD)	6937.85 (704.070)	2386.83 (518.752)	126.041 (15.1427)	62.8319 (12.25621)
GeoMean	6903.36	2334.75	125.159	61.7272
(95% CI)	(6674.44; 7140.13)	(2175.34; 2505.85)	(120.246; 130.273)	(57.9543; 65.7457)
GeocV(CV%)	10.1 (10.1)	21.5 (21.7)	12.1 (12.0)	19.1 (19.5)
SEM	115.748	85.282	2.4895	2.01491
Median	6941.44	2335.06	126.200	60.9600
Min; Max	5657.4; 8289.1	1528.9; 3954.6	102.60; 152.50	45.293; 87.290

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeocV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table

15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Page 20 of 24
Confidential

Merck Serono
EMR 200125-002
Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment C

Subject Number/ Random Number	AUC(0-48) (hr*ng/mL)	AUC(0-48,adj) (hr*ng/mL)	tmax (hr)	AUCextra,adj (hr*ng/mL)#
	4694.8	1624.1	3.00	NE
	5141.4	2139.2	10.10	NE
	4797.1	1573.0	6.02	NE
	5012.9	1629.9	3.00	NE
	5367.9	1854.0	2.02	NE
	4140.0	1497.4	10.00	NE
	4626.4	2094.2	10.00	NE
	4406.3	1347.8	2.00	NE
	4774.5	1633.7	4.02	NE
	4570.5	1385.3	1.52	NE
	5600.1	2720.4	1.50	NE
	5036.1	1903.7	4.00	NE
	5560.0	1679.7	1.50	NE
	4485.1	2023.2	1.50	NE
	4241.8	1300.2	2.08	NE
	4743.7	1798.5	1.52	NE
	5128.5	1547.0	1.00	NE
	4315.5	1564.8	4.00	NE
	4552.3	1857.1	2.50	NE
	4115.6	1904.4	2.52	NE

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.
^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_Z, All Lambda_Z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 23 of 24
ConfidentialTable 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment C

Subject Number/ Random Number	AUC _{0-∞} , adj (hr*ng/mL)#	t _{1/2} (hr)#	λ _z (1/hr)^	V _z /F (L)#	CL/F (L/hr)#
	NE	NE	0.009	NE	NE
	NE	NE	0.024	NE	NE
	NE	NE	0.010	NE	NE
	NE	NE	0.015	NE	NE
	NE	NE	0.008	NE	NE
	NE	NE	0.001	NE	NE
	NE	NE	0.034	NE	NE
	NE	NE	0.008	NE	NE
	NE	NE	0.013	NE	NE
	NE	NE	0.004	NE	NE
	NE	NE	0.001	NE	NE
	NE	NE	0.005	NE	NE
	NE	NE	0.004	NE	NE
	NE	NE	0.010	NE	NE
	NE	NE	0.025	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.009	NE	NE
	NE	NE	0.031	NE	NE
	NE	NE	0.001	NE	NE
	NE	NE	0.018	NE	NE

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_z, All Lambda_z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

EMR 200125-002

Table 15.4.1.1.2 Individual Data and Summary Statistics of Total T4 Pharmacokinetic Parameters

(Pharmacokinetic Population)

Treatment: Treatment C

Page 24 of 24

Confidential

Subject Number/ Random Number	AUC _{0-∞} , adj (hr*ng/mL)#	t _{1/2} (hr)#	λ _z (1/hr)^	V _z /F (L)#	CL/F (L/hr)#
	NE	NE	0.015	NE	NE
	NE	NE	0.005	NE	NE
	NE	NE	0.008	NE	NE
	NE	NE	0.016	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.031	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	NE	NE	NE
	NE	NE	0.026	NE	NE
	NE	NE	0.030	NE	NE
	NE	NE	0.017	NE	NE
	NE	NE	0.012	NE	NE
	NE	NE	0.007	NE	NE
	NE	NE	0.067	NE	NE
	NE	NE	0.012	NE	NE
	NE	NE	0.025	NE	NE
	NE	NE	0.017	NE	NE

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T4: Tetraiodothyronine; NE: Not Estimated.

^: Parameter values are presented but excluded from summary statistics.

#: Due to unreliable Lambda_z, All Lambda_z dependent parameters are not estimated.

*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/Tables/Table

15.4.1.1.2.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 1 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)			
	Predose (Mean)	0.5	1	1.5
	0.532	0.587	0.521	0.606
	0.802	0.697	0.699	0.827
	1.004	1.010	1.100	0.897
	0.813	0.852	0.820	0.771
	0.693	0.648	0.672	0.756
	0.721	0.963	0.959	0.878
	1.057	1.050	1.180	1.290
	0.733	0.760	0.839	0.745
	0.727	0.760	0.791	0.775
	0.672	0.651	0.665	0.858
	1.233	1.180	1.540	0.874
	0.816	0.829	0.809	1.090
	0.840	0.729	0.749	0.844
	0.694	0.651	0.784	0.808
	1.523	1.310	1.260	1.480
	0.901	0.986	0.810	0.607
	0.911	0.873	0.876	0.805
	0.903	0.835	0.869	1.150
	0.920	0.945	1.050	1.050
	0.829	0.899	0.690	0.761

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

EMR200125-002 Page 417 of 658
Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002
Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Page 2 of 36
Confidential

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)			
	Predose (Mean)	0.5	1	1.5
	0.760	0.662	0.747	0.848
	0.678	0.652	0.699	0.785
	0.742	0.709	0.729	0.744
	0.765	0.673	0.690	0.951
	0.677	0.554	0.695	0.873
	0.934	0.812	0.804	0.802
	0.852	0.860	0.961	0.957
	0.769	0.816	0.798	0.833*
	0.788	0.765	0.767	0.871
	0.811	0.939	0.845	0.838
	0.894	0.851	0.879	0.798
	0.969	1.030	0.888	1.210
	1.032	0.878	0.688	0.751
	0.730	0.624	0.892	0.871
	0.720	0.571	0.831	0.914
	1.051	1.040	0.995	1.320
	0.694	0.699	0.735	0.792

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 3 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)			
	Predose (Mean)	0.5	1	1.5
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	0.8430 (0.17964)	0.8203 (0.17424)	0.8466 (0.19000)	0.8927 (0.18919)
GeoMean	0.8269	0.8031	0.8289	0.8757
(95% CI)	(0.7752;0.8820)	(0.7495;0.8605)	(0.7747;0.8869)	(0.8209;0.9341)
GeoCV(CV%)	19.5 (21.3)	20.9 (21.2)	20.5 (22.4)	19.6 (21.2)
SEM	0.02953	0.02864	0.03124	0.03110
Median	0.8110	0.8160	0.8090	0.8440
Min; Max	0.532; 1.523	0.554; 1.310	0.521; 1.540	0.606; 1.480

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono Page 4 of 36
 EMR 200125-002 Confidential
 Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)			
	2	2.5	3	4
	0.654	0.612	0.622	0.632
	0.901	0.839	0.695	0.709
	0.979	1.040	0.923	0.857
	0.852	0.698	0.936	1.030*
	0.649	0.743	0.662	0.637
	0.905	0.861	0.722	0.785
	1.250	1.140	0.863	1.140
	0.985	1.100	0.782	0.702
	0.674	0.729	0.692	0.730
	0.620	0.676	0.856	0.591
	0.939	1.330	1.040	1.300
	0.857	0.898	0.811	0.940
	0.890	0.982	0.835	0.901
	0.781	0.837	0.807	0.719
	1.660	1.220	1.160	1.630
	0.915	0.927	0.877	0.905
	0.825	0.926	1.020	0.889
	0.750	0.894	1.010	1.020
	0.905	0.914	0.816	0.832
	0.814	0.887	0.758	0.837

CI: Confidence Interval; CV3: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
 GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
 specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
 *: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 5 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)			
	2	2.5	3	4
	0.745	0.816	0.794	0.676
	0.650	0.788	0.696	0.749
	0.761	0.953	0.850	0.817
	0.910*	0.812	0.758	0.741
	0.670	0.687	0.645	0.738
	0.813	0.882	0.820	0.807
	0.861	1.120	0.911	0.901
	0.744	0.811	0.801	0.807
	0.875	0.782	0.825	0.827
	0.726	0.832	0.863	0.816
	0.850	1.060	0.985	0.951
	0.942	1.110	0.718	1.010
	1.010	1.070	0.993	0.888
	0.868	0.771	0.622	0.806
	0.992	0.974	0.710	0.986
	1.320	0.905	0.980	0.833
	0.855	0.775	0.757	0.737

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 6 of 36

EMR 200125-002

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)			
	2	2.5	3	4
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean (SD)	0.8756 (0.19914)	0.9027 (0.16132)	0.8274 (0.12807)	0.8615 (0.19361)
GeoMean (95% CI)	0.8573 (0.8018;0.9167)	0.8892 (0.8387;0.9428)	0.8180 (0.7773;0.8608)	0.8439 (0.7899;0.9017)
GeoCV(CV%)	20.3 (22.7)	17.7 (17.9)	15.4 (15.5)	20.1 (22.5)
SEM	0.03274	0.02652	0.02105	0.03183
Median	0.8570	0.8870	0.8160	0.8270
Min; Max	0.620; 1.660	0.612; 1.330	0.622; 1.160	0.591; 1.630

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 7 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)				
	6	8	10	12	18
	0.593	0.601	0.685	0.625	0.620
	0.823	0.810	0.910	0.830	0.813
	1.010	1.210	0.825	0.849	1.000
	0.786	0.960	0.841	0.841	0.778
	0.775*	0.753	0.863	0.749	0.645
	0.930	0.917	1.170	0.736	1.000
	1.090	1.050	0.978	0.615	0.814
	0.686	0.742	0.785	0.727	0.682
	0.674	0.614	0.634	0.743	0.724
	0.781	0.774	0.767	0.703	0.744
	0.999	0.591	1.100	0.896*	1.030
	1.140	1.240	0.988	1.080	1.030
	0.896	0.861	0.730	0.780	0.717
	0.709	0.670	0.921	0.707	0.789
	1.150	1.420	1.480	1.310	1.220
	0.871	0.875	0.818	0.896	0.731
	0.842	0.856	0.795	0.891	1.080
	0.813	0.824	0.762	0.667	0.765
	1.030	1.170	0.848	0.768	0.734
	0.613	0.710	0.789	0.761	0.729

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 8 of 36

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)				
	6	8	10	12	18
	0.771	0.748	0.737	0.662	0.684
	0.713	0.815	0.797	0.793	0.828
	0.719*	0.741	0.841	0.800	0.841
	0.790	0.746	0.824	0.645	0.716
	0.683	0.772	0.725	0.749	0.600
	0.843	0.837	0.893	0.817	0.778
	0.918	0.798	0.831	1.020	0.890
	0.845	0.872	0.916	0.949	0.838
	0.777	0.738	0.819	0.711	0.793
	0.679	0.880	0.813	0.778	0.682
	0.978	0.909	0.818	1.120	0.883
	0.990	1.080	0.852	0.824	0.937
	1.180	0.787	1.140	0.890	0.858
	0.688	0.795	0.795	0.808	0.632
	0.726	0.747	0.605	0.739	0.670
	0.882	1.270	1.240	1.220	0.936
	0.754	0.842	0.896	0.814	0.675

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 9 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)				
	6	8	10	12	18
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	0.8418 (0.15318)	0.8655 (0.19228)	0.8711 (0.17065)	0.8247 (0.15661)	0.8077 (0.14300)
GeoMean (95% CI)	0.8288 (0.7811;0.8794)	0.8470 (0.7908;0.9073)	0.8570 (0.8076;0.9094)	0.8119 (0.7660;0.8605)	0.7963 (0.7526;0.8424)
GeoCV(CV%)	17.9 (18.2)	20.8 (22.2)	17.9 (19.6)	17.6 (19.0)	17.0 (17.7)
SEM	0.02518	0.03161	0.02806	0.02575	0.02351
Median	0.8130	0.8150	0.8250	0.7930	0.7780
Min; Max	0.593; 1.180	0.591; 1.420	0.605; 1.480	0.615; 1.310	0.600; 1.220

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 10 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)			
	24	36	48	72
	0.600	0.602	0.656	0.698
	0.778	0.930	0.894	0.812
	1.020	1.040	1.040	1.220
	0.949	1.010	1.000	0.846
	0.812	0.722	0.816	0.916
	0.630	1.020	1.040	0.989
	1.230	0.788	0.878	0.807
	0.739	0.787	0.821	0.877
	0.782	0.902	0.801	0.800
	0.816	0.765	0.739	1.010
	1.090	0.943	0.907	0.914
	1.160	0.924	0.980	0.942
	0.760	0.790	0.810	1.040
	0.908	0.900	0.908	0.965
	0.955	0.984	0.980	0.940
	0.975	0.871	0.835	0.855
	1.010	1.050	0.971	0.783
	0.874	0.790	0.799	0.991*
	0.835	0.996	0.998	0.842
	0.847	0.737	0.778	0.842

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 11 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)			
	24	36	48	72
	0.742	0.740	0.711	0.748
	0.832	0.753	0.777	0.804
	0.797	0.902	0.796	0.954
	0.732	0.746	0.676	0.803
	0.742	0.711	0.818	0.780
	0.930	0.921	0.978	0.924
	0.929	0.902	1.030*	0.933
	0.859	0.704	0.780	0.830
	0.871	0.895	0.845	0.801
	0.765	0.831	0.941	0.950
	0.988	0.940	1.100	0.898
	1.010	1.040	1.000	0.838*
	0.680	0.810	0.829	0.907
	0.686	0.860	0.875	0.883
	0.897	0.442	0.643	0.883
	0.982	1.350	1.090	1.750
	0.836	0.797	0.780	0.742

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono Page 12 of 36
 EMR 200125-002 Confidential
 Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment A

Subject Number/ Random Number	Sample Times (h)			
	24	36	48	72
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	0.8662 (0.14027)	0.8620 (0.15407)	0.8735 (0.12135)	0.9059 (0.17321)
GeoMean (95% CI)	0.8553 (0.8106;0.9025)	0.8481 (0.7968;0.9027)	0.8652 (0.8255;0.9068)	0.8937 (0.8483;0.9416)
GeoCV(CV%)	16.2 (16.2)	18.9 (17.9)	14.2 (13.9)	15.8 (19.1)
SEM	0.02306	0.02533	0.01995	0.02847
Median	0.8470	0.8710	0.8450	0.8830
Min; Max	0.600; 1.230	0.442; 1.350	0.643; 1.100	0.698; 1.750

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
 GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
 specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;

*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

EMR200125-002 Page 428 of 658
Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002
Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Page 13 of 36
Confidential

Treatment: Treatment B

Subject Number/ Random Number	Predose (Mean)	Sample Times (h)		
		0.5	1	1.5
	0.687	0.754	0.710	0.822
	0.787	0.784	0.797	0.658
	0.916	0.851	0.913	1.080
	0.876	0.894	0.826	0.810
	0.799	0.790	0.687	0.985
	0.764	0.760	0.814	0.890
	0.897	0.988	1.090	0.835
	0.729	0.838	0.728	0.739
	0.642	0.571	0.615	0.597
	0.867	0.849	0.730	0.913
	1.032	0.930	1.020	1.070
	0.845	0.658	1.050	1.110
	0.705	0.683	0.666	0.802
	0.748	0.891	0.950	0.757
	0.827	0.813	0.766	0.890
	0.942	0.702*	0.806	0.983
	0.937	1.070*	1.020	0.835
	0.700	1.010	0.870	0.938
	0.716	0.836	0.811	0.795
	0.755	0.706	0.772	0.763

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;

*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 14 of 36

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)			
	Predose (Mean)	0.5	1	1.5
	0.672	0.662	0.808	0.712
	0.718	0.801	0.779	0.852
	0.840	0.736	0.779	0.935
	0.852	0.819	0.788	0.768
	0.639	0.711	0.572	0.716
	0.893	0.819	0.907	0.950
	0.805	0.791	0.897	0.762
	0.818	0.831	0.791	0.915
	0.972	0.821	1.020	0.920
	0.744	0.797	0.793	0.688
	0.925	0.831	0.935	0.941
	0.789	0.769	0.742	0.807
	0.974	0.846	0.886	1.270
	0.738	0.586	0.709	0.726
	0.808	0.769	0.942	1.040
	0.945	0.879	1.140	1.200
	0.815	0.753	0.857	1.070

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 15 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)			
	Predose (Mean)	0.5	1	1.5
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	0.8140 (0.10037)	0.8000 (0.10483)	0.8375 (0.13086)	0.8796 (0.15256)
GeoMean	0.8080	0.7932	0.8276	0.8671
(95% CI)	(0.7754;0.8420)	(0.7589;0.8291)	(0.7857;0.8718)	(0.8191;0.9179)
GeoCV(CV%)	12.4 (12.3)	13.3 (13.1)	15.7 (15.6)	17.2 (17.3)
SEM	0.01650	0.01723	0.02151	0.02508
Median	0.8080	0.8010	0.8080	0.8520
Min; Max	0.639; 1.032	0.571; 1.070	0.572; 1.140	0.597; 1.270

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine; *: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table 15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 16 of 36

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)			
	2	2.5	3	4
	0.933	0.754	0.822	0.872
	0.669	0.850	0.684	0.912
	0.885	1.140	0.960	0.811
	0.994	0.937	0.825	0.795
	0.898	0.756	0.805	0.867
	0.938	0.676	0.849	0.906
	0.977*	1.060	0.853	1.170
	0.702	0.692	0.678	0.733
	0.663	0.664	0.746	0.753
	0.817	0.845	0.832	0.687*
	1.040	1.140	1.040	0.843
	0.919	0.858	0.662	0.945
	0.601	0.673	0.763	0.867
	0.683	0.966	0.818	0.863
	1.020	0.835	0.759	1.030
	0.992	0.937	0.854	1.120
	0.961	0.866	0.885	0.830
	0.752	0.843	0.907	0.771
	0.645	0.776	0.659	0.867
	0.695	0.739	0.703	0.774

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 17 of 36

EMR 200125-002

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)			
	2	2.5	3	4
	0.719	0.647	0.672	0.601
	0.826	0.883	0.866	0.833
	0.880	0.979	0.867	0.903
	0.854	0.831	0.846	0.676
	0.654	0.605	0.702	0.574
	0.884	1.080	0.816	0.992
	0.768	1.070	0.880	0.893
	0.868	0.786	0.907	0.871
	1.000	0.973	0.835	0.951
	0.692	0.743	0.763	0.799
	1.110	1.260	1.020	0.862
	0.912	0.990	0.736	0.664
	1.150	1.320	1.140	1.040
	0.656	0.666	0.668	0.620
	0.613	0.807	0.742	0.880
	0.790	1.070	1.090	1.230
	0.870	0.786	0.801	0.883

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e2i0898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono Page 18 of 36
 EMR 200125-002 Confidential
 Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)			
	2	2.5	3	4
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	0.8386 (0.14727)	0.8785 (0.17612)	0.8231 (0.11856)	0.8564 (0.14599)
GeoMean (95% CI)	0.8260 (0.7784;0.8764)	0.8621 (0.8077;0.9201)	0.8152 (0.7782;0.8540)	0.8444 (0.7975;0.8941)
GeoCV(CV%)	17.9 (17.6)	19.7 (20.0)	14.0 (14.4)	17.3 (17.0)
SEM	0.02421	0.02895	0.01949	0.02400
Median	0.8680	0.8450	0.8220	0.8670
Min; Max	0.601; 1.150	0.605; 1.320	0.659; 1.140	0.574; 1.230

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
 GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
 specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
 *: Measurement taken outside the allowed windows allowance.
 Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 19 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)				
	6	8	10	12	18
	0.790	0.847	0.769	0.769	0.645
	0.908*	0.816	0.823	0.825	1.100
	0.951	1.030	1.030	0.888	0.900
	0.820	0.854	1.120	0.866	0.992
	0.780	0.833	1.010	0.796	0.808
	0.818	0.885	1.140	0.890	0.808
	1.060	0.691	0.973	0.822	0.974
	0.742	0.653	0.858	0.734	0.703
	0.682	0.589	0.498	0.674	0.627
	0.777	0.869	0.928	0.972	0.843
	0.972	1.000	0.895	0.958	1.030
	1.040	0.968	0.864	0.944	0.858
	0.757	0.739	0.780	0.659	0.724
	0.855	0.833	0.817	0.866	0.857
	0.904	1.020	0.833	1.010	0.834
	0.827	0.756	0.878	0.862	1.000
	1.010	0.957	0.847	0.872	0.882
	0.781	0.853	0.920	0.709	0.664
	0.706	0.860	0.815	0.619	0.768
	0.678	0.704	0.661	0.758	0.673

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002
Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)Page 20 of 36
Confidential

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)				
	6	8	10	12	18
	0.715	0.733	0.704	0.715	0.679
	0.837	0.835	0.885	0.880	0.770
	0.906	0.803	0.759	0.866	0.783
	0.849	0.831	0.703	0.691	0.703
	0.692	0.633	0.638	0.556	0.588
	0.934	0.948	0.974	0.866	0.920
	0.798	0.848	0.806	0.869	0.808
	0.826	0.892	0.779	0.830	0.784
	0.901	0.902	0.857	0.834	0.805
	0.757	0.723	0.646	0.779	0.750
	0.829	0.892	0.894	0.836	0.870
	0.805	0.852	0.807	0.859	0.815
	0.948	1.260	1.040	1.100	1.080
	0.768	0.648	0.753	0.734	0.621
	0.904	0.983	0.654	0.935	0.915
	0.753	1.170	0.935	0.755	0.716
	0.808	0.946	0.793	0.753	0.750

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 21 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)				
	6	8	10	12	18
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	0.8348 (0.09853)	0.8556 (0.14141)	0.8402 (0.13689)	0.8203 (0.11122)	0.8121 (0.12928)
GeoMean	0.8293	0.8444	0.8289	0.8128	0.8023
(95% CI)	(0.7978;0.8621)	(0.7995;0.8919)	(0.7835;0.8770)	(0.7759;0.8514)	(0.7611;0.8456)
GeoCV(CV%)	11.7 (11.8)	16.5 (16.5)	17.0 (16.3)	14.0 (13.6)	15.9 (15.9)
SEM	0.01620	0.02325	0.02250	0.01828	0.02125
Median	0.8200	0.8520	0.8330	0.8340	0.8080
Min; Max	0.678; 1.060	0.589; 1.260	0.498; 1.140	0.556; 1.100	0.588; 1.100

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002
Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)Page 22 of 36
Confidential

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)			
	24	36	48	72
	0.804	0.784	0.782	0.791
	0.783	0.852	0.905	0.846
	1.150	1.010	1.090	1.190
	0.905	1.020	0.883	0.920
	0.845	0.777	0.851	0.878*
	0.866	0.859	0.993	0.741
	1.190	0.766	0.954	0.859
	0.896	0.801	0.758	0.809
	0.644	0.668	0.646	0.617
	0.998	0.682	0.892	1.060
	1.210	0.924	1.180	0.857
	0.895	1.060	1.280	1.500
	0.880	0.654	0.794	0.788
	0.940	0.921	1.020	0.999
	1.080	0.758	0.750	0.792
	0.901	0.755	0.901	1.130
	0.899	1.030	1.010	0.904
	0.831	0.736	0.754	0.777
	0.774	0.892	0.832	0.914
	0.726	0.760	0.879	0.845

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 23 of 36

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)			
	24	36	48	72
	0.661	0.724	0.802*	0.729
	0.916	0.884	0.856	0.961
	1.010	0.747	0.931	0.942
	0.730	0.726	0.771	0.793
	0.618	0.676	0.730	0.678
	0.940	0.851	0.817*	0.823*
	0.788	0.833	0.938	0.918
	0.883	0.817	0.719	0.876
	0.878	0.932	0.839	0.918
	0.776	0.843	0.941	1.010
	1.020	0.790	0.910	1.220
	0.638	0.972	1.140	0.934
	0.884	1.230	1.180	1.140
	0.711	0.626	0.800	0.796
	0.931	0.890	0.518	0.739
	1.040	0.871	1.030	1.090
	0.731	0.815	0.730	0.874

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

EMR200125-002 Page 439 of 658

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono Page 24 of 36
EMR 200125-002 Confidential
Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment B

Subject Number/ Random Number	Sample Times (h)			
	24	36	48	72
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean (SD)	0.8749 (0.14751)	0.8361 (0.12818)	0.8866 (0.15761)	0.9097 (0.17109)
GeoMean (95% CI)	0.8629 (0.8158; 0.9128)	0.8270 (0.7872; 0.8690)	0.8731 (0.8225; 0.9268)	0.8955 (0.8445; 0.9497)
GeoCV(CV%)	17.0 (16.9)	14.9 (15.3)	18.1 (17.8)	17.7 (18.8)
SEM	0.02425	0.02107	0.02591	0.02813
Median	0.8830	0.8170	0.8790	0.8760
Min; Max	0.618; 1.210	0.626; 1.230	0.518; 1.280	0.617; 1.500

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 25 of 36

EMR 200125-002

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)			
	Predose (Mean)	0.5	1	1.5
	0.896	0.825	0.839	0.777
	0.734	0.845	0.679	0.663
	0.984	0.840	0.954	0.933
	0.914	0.768*	0.909	0.826
	0.780	0.870	0.832	0.834
	0.862	0.756	0.854	1.040
	0.925	1.070	1.110	0.924
	0.833	0.812	0.795	0.905
	0.763	0.740	0.721	0.891
	0.911	0.870	0.879	1.040
	1.066	1.190	1.090	0.900
	0.779	0.905*	0.764	0.909
	0.842	0.848	0.763	0.824
	0.736	0.758	0.729	0.645
	0.872	0.828	0.772	1.070
	0.928	0.807	1.020	0.887
	0.878	0.737	0.789	0.837
	0.812	0.810	1.050	0.832
	0.826	0.943	0.990	0.996
	0.748	0.679	0.610	0.858

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;

*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 26 of 36

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)			
	Predose (Mean)	0.5	1	1.5
	0.737	0.660	0.732	0.964
	0.643	0.607	0.698	0.663
	0.797	0.689	0.829	0.709
	0.734	0.772	0.677	0.828
	0.702	0.644	0.584	0.626
	0.896	0.724	0.848	0.965
	0.840	0.803	0.880	0.854
	0.791	0.808	0.843*	0.929
	0.796	0.681	0.819	0.728
	0.715	0.753	0.693	0.732
	0.738	0.728	0.606	0.735
	1.085	0.996	1.150	1.220
	0.803	0.704	0.834	1.000
	0.701	0.522	0.696	0.746
	0.905	0.903	0.809	0.788
	0.813	1.260	0.946	0.982
	0.811	0.719	0.789	0.867

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 27 of 36

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)			
	Predose (Mean)	0.5	1	1.5
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	0.8269 (0.09767)	0.8074 (0.14665)	0.8265 (0.14021)	0.8629 (0.13085)
GeoMean (95% CI)	0.8215 (0.7905;0.8537)	0.7955 (0.7511;0.8425)	0.8153 (0.7711;0.8621)	0.8533 (0.8110;0.8977)
GeoCV(CV%)	11.6 (11.8)	17.4 (18.2)	16.8 (17.0)	15.3 (15.2)
SEM	0.01606	0.02411	0.02305	0.02151
Median	0.8120	0.8030	0.8190	0.8580
Min; Max	0.643; 1.085	0.522; 1.260	0.584; 1.150	0.626; 1.220

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine; *: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table 15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 28 of 36

EMR 200125-002

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)			
	2	2.5	3	4
	0.760	0.803	0.871	0.735
	0.674	0.647	0.778	0.632
	0.821	1.090	1.040	1.110
	0.816	0.833	0.951	0.899
	0.731	0.821	0.825	0.720
	0.756	0.759	0.857	0.748
	1.160	0.762	0.782	0.798
	0.934	0.800	0.826	0.837
	0.738	0.726	0.697	0.756
	0.923	0.794	0.895	0.798
	0.775	1.030	0.951	0.787
	0.910	0.830	0.719	0.780
	0.877	0.915	0.880	0.865
	0.762	0.819	0.921	0.944
	0.985*	0.759	1.030	0.867
	0.848	0.963	0.800	0.894*
	1.000	0.860	0.724	0.668
	0.854	0.786	0.917	0.917
	0.798	0.944	0.912	0.803
	0.704	0.825	0.684	0.854

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine; *: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/Tables/Table 15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 29 of 36
Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)			
	2	2.5	3	4
	0.846	0.924	0.818	0.921
	0.693	0.742	0.902	0.754
	0.785	0.887	0.885	0.871
	0.697	0.875	0.697	0.784
	0.643	0.655	0.542	0.688
	0.871	0.815	0.744	0.864
	0.747	1.080	0.813	0.905
	0.825	0.857	0.770	0.917
	0.852	0.857	0.758	0.728
	0.662	0.723	0.667	0.695
	0.893	1.020	0.748	0.702
	1.110	0.937	0.979	1.310
	0.952	0.936	0.921	1.160
	1.010	0.604	0.588	0.568
	0.898	0.846	1.020	1.110
	0.902	1.100	0.993	0.886
	0.899	0.763	0.854	0.910

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine; *: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table 15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono Page 30 of 36
 EMR 200125-002 Confidential
 Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)			
	2	2.5	3	4
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	0.8408 (0.12013)	0.8483 (0.11946)	0.8313 (0.12071)	0.8428 (0.14945)
GeoMean	0.8328	0.8402	0.8223	0.8309
(95% CI)	(0.7947;0.8726)	(0.8017;0.8806)	(0.7817;0.8651)	(0.7853;0.8791)
GeoCV(CV%)	14.1 (14.3)	14.1 (14.1)	15.3 (14.5)	17.1 (17.7)
SEM	0.01975	0.01964	0.01985	0.02457
Median	0.8460	0.8300	0.8260	0.8370
Min; Max	0.643; 1.160	0.604; 1.100	0.542; 1.040	0.568; 1.310

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
 GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
 specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
 *: Measurement taken outside the allowed windows allowance.
 Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 31 of 36

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)				
	6	8	10	12	18
	0.766	0.834	0.856	0.760	0.749
	0.695	0.956	0.973	0.700	0.735
	1.080	1.080	0.917	0.932	0.944
	1.050	0.890	0.982	0.811	0.865
	0.815	0.842	0.955	0.830	0.732
	0.730	1.460	0.886	0.871	0.742
	0.952	0.774	0.954	0.858	0.813
	0.735*	0.771	0.900	0.755*	0.815
	0.688	0.674	0.673	0.765	0.701
	0.919	0.951	0.832	0.888	0.763
	1.090	0.920	1.000	0.989	0.978
	0.938	1.120	0.843	0.791	0.785
	0.679	0.877	0.789	0.688	0.735
	0.755*	0.762	0.875	0.898*	0.763
	0.992	0.759	0.883	0.970	0.755
	0.857	0.768	0.892	1.040	0.944
	0.794	0.951	0.594	0.818	0.834
	0.762	0.861	0.726	0.904	0.602
	0.993	0.969	0.791	0.781	0.793
	0.604	0.586	0.795	0.765	0.608

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;

*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono

Page 32 of 36

EMR 200125-002

Confidential

Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)				
	6	8	10	12	18
	0.742	0.865	0.874	0.628	0.699
	0.823	0.709	0.712	0.679	0.735
	0.763	0.771	0.728	0.750	0.832
	0.700	0.780	0.580	0.686	0.767
	0.717	0.701	0.728	0.680	0.806
	0.762	0.711	0.790	0.705	0.706
	0.826	0.810	0.855	0.876	0.850
	0.796	0.745	0.925	0.826	0.839
	0.701	0.742	0.768	0.683	0.727
	0.812	0.695	0.642	0.733	0.644
	0.804	0.732	0.682	0.746	0.711
	1.140	0.872	0.806	0.894	0.966
	0.866	0.889	0.965	1.000	0.890
	0.665	0.721	0.705	0.566	0.575
	0.564	0.835	0.780	0.603	0.679
	0.857*	0.908	0.648	0.912	1.320
	0.783	0.889	0.851	0.759	0.703

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono Page 33 of 36
 EMR 200125-002 Confidential
 Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)				
	6	8	10	12	18
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	0.8166 (0.13650)	0.8427 (0.15308)	0.8150 (0.11277)	0.7984 (0.11473)	0.7866 (0.13229)
GeoMean	0.8060	0.8310	0.8071	0.7903	0.7771
(95% CI)	(0.7634;0.8510)	(0.7866;0.8779)	(0.7693;0.8467)	(0.7530;0.8295)	(0.7381;0.8181)
GeoCV(CV%)	16.4 (16.7)	16.6 (18.2)	14.4 (13.8)	14.6 (14.4)	15.5 (16.8)
SEM	0.02244	0.02517	0.01854	0.01886	0.02175
Median	0.7940	0.8340	0.8320	0.7810	0.7630
Min; Max	0.564; 1.140	0.586; 1.460	0.580; 1.000	0.566; 1.040	0.575; 1.320

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
 GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
 specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
 *: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono Page 34 of 36
 EMR 200125-002 Confidential
 Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)			
	24	36	48	72
	0.776	0.803	0.682	0.825
	0.881	0.833	0.820	0.716
	1.050	0.950	1.180	0.957
	0.928	0.908	1.000	0.986
	0.838	0.788	0.862	0.916
	0.675	0.834	1.220*	0.959
	0.832	1.030	0.912	0.607
	0.842	0.797	0.822	0.918
	0.755	0.701	0.666	0.721
	0.674	0.646	0.933	1.200
	1.070	1.180	1.090	0.919*
	0.772	0.985	1.330	1.120*
	0.891	0.806	0.860	0.906
	0.914	0.884	1.020	0.901
	0.984	0.710	0.999	0.951
	0.764	0.718	0.839	0.815
	0.918	0.801	0.911	0.965
	0.705	0.857	0.856	0.697*
	0.747	0.796	0.902	0.981
	0.762	0.797	0.722	0.715

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
 GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
 specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
 *: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.1.1.3.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono Page 35 of 36
EMR 200125-002 Confidential
Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)			
	24	36	48	72
	0.804	0.766	0.860	0.859
	0.753	0.706	0.802	0.937
	0.859	0.769	0.732	0.811
	0.827	0.878	0.686	0.952
	0.716	0.711	0.767	0.866
	0.744	0.740	0.793	0.809
	0.957	0.776	0.779*	0.914
	0.914	0.701	0.733	0.872
	0.828	0.797	0.738	0.789
	0.642	0.918	0.918	0.834
	0.759	0.802	0.919	0.770
	0.947	1.080	0.840	0.873
	0.953	0.977	1.100	1.360
	0.813	0.737	0.941	0.753
	0.848	0.901	1.230	0.898
	0.903	1.090	1.120	0.885
	0.830	0.908	0.950	0.913

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
*: Measurement taken outside the allowed windows allowance.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono Page 36 of 36
 EMR 200125-002 Confidential
 Table 15.4.1.1.3 Individual Data and Summary Statistics of Concentrations for Total T3 (ng/mL) (Pharmacokinetic Population)

Treatment: Treatment C

Subject Number/ Random Number	Sample Times (h)			
	24	36	48	72
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean (SD)	0.8345 (0.10245)	0.8400 (0.12248)	0.9063 (0.16499)	0.8884 (0.13884)
GeoMean (95% CI)	0.8284 (0.7953;0.8629)	0.8319 (0.7940;0.8715)	0.8926 (0.8418;0.9463)	0.8785 (0.8354;0.9237)
GeoCV (CV%)	12.3 (12.3)	14.0 (14.6)	17.7 (18.2)	15.1 (15.6)
SEM	0.01684	0.02014	0.02712	0.02282
Median	0.8300	0.8020	0.8620	0.8980
Min; Max	0.642; 1.070	0.646; 1.180	0.666; 1.330	0.607; 1.360

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
 GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with concentrations at
 specific sampling time; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine;
 *: Measurement taken outside the allowed windows allowance.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.1.1.3.sas

10DEC2014 00:20



EMR200125-002 Page 452 of 658

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002

Page 1 of 9
Confidential

Table 15.4.1.1.4 Individual Data and Summary Statistics of Total T3 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment A

Subject Number/ Random Number	AUC0-48 (hr*ng/mL)	AUC0-72 (hr*ng/mL)	Cmax (ng/mL)	tmax (hr)
	29.57	45.81	0.698	72.28
	40.57	61.09	0.930	35.68
	48.16	74.54*	1.240	0.00
	44.31	66.04*	1.030	4.10
	35.90	56.69	0.916	72.53
	43.28	66.91*	1.170	10.12
	44.71	64.92	1.290	1.50
	36.50	56.87	1.100	2.50
	37.49	56.68*	0.902	35.83
	36.26	56.59*	1.010	71.13
	47.52	69.37	1.540	1.00
	48.97	72.05	1.240	8.02
	37.87	59.99	1.040	72.90
	40.40	62.28*	0.965	71.35
	54.05	77.12	1.660	2.00
	41.60	61.87	0.986	0.50
	46.97	67.66*	1.080	18.02
	38.96	60.22	1.150	1.50
	43.53	64.88*	1.170	8.02
	36.78	55.85*	0.899	0.50
	34.75	52.09*	0.848	1.52

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine. NE: Not Estimated.
*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.4.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 2 of 9
ConfidentialTable 15.4.1.1.4 Individual Data and Summary Statistics of Total T3 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment A

Subject Number/ Random Number	AUC0-48 (hr*ng/mL)	AUC0-72 (hr*ng/mL)	Cmax (ng/mL)	tmax (hr)
	37.58	55.88*	0.832	23.98
	39.57	59.97*	0.954	71.25
	35.09	52.20*	0.951	1.52
	34.55	53.74	0.873	1.52
	42.51	65.11*	0.978	47.70
	44.44	68.05	1.120	2.50
	38.90	58.21	0.949	12.00
	39.98	59.22*	0.895	35.72
	38.70	60.53*	0.950	71.08
	46.57	70.39*	1.120	12.00
	47.24	69.37	1.210	1.50
	40.28	60.64*	1.180	0.00
	37.24	58.01*	0.892	1.00
	32.28	50.31*	0.992	2.00
	53.79	87.89	1.750	72.35
	37.81	56.07	0.896	10.02

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine. NE: Not Estimated.
*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.4.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 3 of 9
ConfidentialTable 15.4.1.1.4 Individual Data and Summary Statistics of Total T3 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment A

Subject Number/ Random Number	AUC0-48 (hr*ng/mL)	AUC0-72 (hr*ng/mL)	Cmax (ng/mL)	tmax (hr)
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	40.936 (5.6091)	62.030 (8.1808)	1.0650 (0.22190)	
GeoMean (95% CI)	40.571 (38.780;42.444)	61.528 (58.953;64.215)	1.0453 (0.9809;1.1140)	
GeoCV(CV%)	13.6 (13.7)	12.9 (13.2)	19.3 (20.8)	
SEM	0.9221	1.3449	0.03648	
Median	39.975	60.531	0.9920	8.017
Min; Max	29.57; 54.05	45.81; 87.89	0.698; 1.750	0.00; 72.90

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine. NE: Not Estimated.
 *: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.
 Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.1.1.4.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 4 of 9
ConfidentialTable 15.4.1.1.4 Individual Data and Summary Statistics of Total T3 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment B

Subject Number/ Random Number	AUC0-48 (hr*ng/mL)	AUC0-72 (hr*ng/mL)	Cmax (ng/mL)	tmax (hr)
	37.18	55.96*	0.933	2.00
	41.58	62.43*	1.100	18.03
	48.55	75.05*	1.190	71.25
	44.91	66.38*	1.120	10.02
	39.43	60.15	1.010	10.02
	42.41	62.50*	1.140	10.00
	44.99	66.43*	1.190	23.88
	37.51	56.31	0.896	23.92
	31.07	45.85*	0.753	4.00
	40.42	63.17*	1.060	71.28
	49.51	73.43*	1.210	23.88
	47.62	80.91	1.500	72.87
	35.71	55.05*	0.880	23.97
	43.44	67.37*	1.020	48.07
	42.20	60.70	1.080	24.00
	41.71	66.09	1.130	72.10
	45.47	68.40	1.070	0.87
	36.96	55.31*	1.010	0.50
	38.42	59.36*	0.914	71.97
	35.79	56.39*	0.879	47.90
	34.04	52.05*	0.808	1.00

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation;
GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter
calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine. NE: Not Estimated.
*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.4.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 5 of 9
ConfidentialTable 15.4.1.1.4 Individual Data and Summary Statistics of Total T3 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment B

Subject Number/ Number	AUC0-48 (hr*ng/mL)	AUC0-72 (hr*ng/mL)	Cmax (ng/mL)	tmax (hr)
	41.38	62.87*	0.961	71.63
	41.01	62.99*	1.010	23.93
	35.57	54.33	0.896	0.00
	30.95	47.76*	0.730	48.03
	42.89	62.56	1.080	2.50
	40.24	62.53	1.070	2.50
	39.30	57.86*	0.915	1.50
	42.23	62.73*	1.020	1.00
	38.49	61.55*	1.010	71.62
	42.70	67.86*	1.260	2.50
	41.21	66.14	1.140	48.78
	52.59	80.43	1.320	2.50
	32.97	51.84*	0.800	47.83
	40.23	54.87*	1.040	1.50
	44.38	69.83	1.230	4.02
	37.60	56.84	1.070	1.50

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine. NE: Not Estimated.
*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.4.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 6 of 9
ConfidentialTable 15.4.1.1.4 Individual Data and Summary Statistics of Total T3 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment B

Subject Number/ Random Number	AUC0-48 (hr*ng/mL)	AUC0-72 (hr*ng/mL)	Cmax (ng/mL)	tmax (hr)
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean (SD)	40.613 (4.8717)	61.953 (7.9329)	1.0391 (0.16066)	
GeoMean (95% CI)	40.328 (38.734;41.987)	61.466 (58.910;64.133)	1.0270 (0.9753;1.0815)	
GeoCV(CV%)	12.1 (12.0)	12.8 (12.8)	15.6 (15.5)	
SEM	0.8009	1.3042	0.02641	
Median	41.012	62.501	1.0400	18.033
Min; Max	30.95; 52.59	45.85; 80.91	0.730; 1.500	0.00; 72.87

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine. NE: Not Estimated.
*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.4.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 7 of 9
ConfidentialTable 15.4.1.1.4 Individual Data and Summary Statistics of Total T3 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment C

Subject Number/ Random Number	AUC0-48 (hr*ng/mL)	AUC0-72 (hr*ng/mL)	Cmax (ng/mL)	tmax (hr)
	37.13	55.16	0.938	0.00
	38.76	57.16*	0.973	10.10
	48.58	74.07	1.180	47.47
	43.90	67.73	1.050	6.03
	39.06	60.41	0.955	10.05
	41.09	67.46	1.460	8.02
	43.44	61.39	1.160	2.02
	39.02	59.92	0.934	2.00
	34.31	50.54*	0.891	1.48
	37.30	62.51*	1.200	71.63
	50.86	75.09	1.190	0.50
	44.54	74.06	1.330	48.02
	38.96	59.67*	0.915	2.50
	42.12	64.78*	1.020	47.62
	41.39	64.81	1.070	1.50
	39.76	59.34*	1.040	12.02
	40.16	62.68	1.000	2.00
	37.98	56.69	1.050	1.00
	39.60	61.80*	0.996	1.52
	35.20	52.02*	0.858	1.52
	37.51	58.14	0.964	1.50

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine. NE: Not Estimated.
 *: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.
 Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/Tables/Table
 15.4.1.1.4.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 8 of 9
ConfidentialTable 15.4.1.1.4 Individual Data and Summary Statistics of Total T3 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment C

Subject Number/ Random Number	AUC0-48 (hr*ng/mL)	AUC0-72 (hr*ng/mL)	Cmax (ng/mL)	tmax (hr)
	35.36	55.91*	0.937	71.58
	37.93	56.41*	0.887	2.50
	37.35	56.96	0.952	72.17
	34.57	53.95*	0.866	71.80
	36.15	55.38	0.972	0.00
	40.53	60.71	1.080	2.50
	38.48	57.17*	0.929	1.52
	36.73	54.94*	0.857	2.50
	36.85	57.17*	0.918	36.30
	37.40	57.65	1.020	2.50
	47.18	67.72	1.350	0.00
	46.51	75.66*	1.360	71.70
	35.00	54.71*	1.010	2.00
	41.51	66.74	1.230	47.40
	49.08	73.09	1.320	18.03
	40.55	62.94	0.950	48.85

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine. NE: Not Estimated.
*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.4.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 9 of 9
ConfidentialTable 15.4.1.1.4 Individual Data and Summary Statistics of Total T3 Pharmacokinetic Parameters
(Pharmacokinetic Population)
Treatment: Treatment C

Subject Number/ Random Number	AUC0-48 (hr*ng/mL)	AUC0-72 (hr*ng/mL)	Cmax (ng/mL)	tmax (hr)
n(missing)	37 (0)	37 (0)	37 (0)	37 (0)
Mean(SD)	40.050 (4.2284)	61.420 (6.7321)	1.0490 (0.15952)	
GeoMean (95% CI)	39.844 (38.516;41.218)	61.075 (58.942;63.285)	1.0381 (0.9894;1.0891)	
GeoCV(CV%)	10.2 (10.6)	10.7 (11.0)	14.5 (15.2)	
SEM	0.6951	1.1068	0.02623	
Median	39.021	59.919	1.0000	2.500
Min; Max	34.31; 50.86	50.54; 75.66	0.857; 1.460	0.00; 72.17

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; GeoCV: Geometric Coefficient of Variation; GeoMean: Geometric Mean; Max: Maximum Value; Min: Minimum Value; n: The number of subjects with specific parameter calculable; SD: Standard Deviation; SEM: Standard Error of the Mean; T3: Triiodothyronine. NE: Not Estimated.
*: AUC(0-tlast) was used. Normalization to exactly 72 hours was not possible because of invalid Lambda_z.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.1.1.4.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 1 of 2
Confidential

Table 15.4.3.1 Summary of ANOVA of Primary Pharmacokinetic Parameters for T4 (Pharmacokinetic Population)

Parameter	Treatment	N	Geo-LSMean	Ratio (Treatments) (%)	95% CI of Ratio	Intra-CV (%)
AUC ₀₋₇₂ (hr*ng/mL)	B	37	6780.981	100.1	97.6 - 102.7	5.4
	A	37	6772.424			
	C	37	6884.607	101.7	99.1 - 104.2	5.4
	A	37	6772.424			
	C	37	6884.607	101.5	99.0 - 104.1	5.4
	B	37	6780.981			
C _{max} (ng/mL)	B	37	125.1199	101.8	98.4 - 105.3	7.3
	A	37	122.9188			
	C	37	125.0102	101.7	98.3 - 105.2	7.3
	A	37	122.9188			
	C	37	125.0102	99.9	96.6 - 103.3	7.3
	B	37	125.1199			

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; Geo-LSMean: Geometric Least Square Mean;
 N: Number of subjects included in the analysis. T4: Tetraiodothyronine;
 Subjects 1017,1033,1048,1079 and 1090 were excluded from the PK Population.
 Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;
 Source: Appendix 16.1.9.1

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.3.1.sas

18DEC2014 00:14

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 2 of 2
Confidential

Table 15.4.3.1 Summary of ANOVA of Primary Pharmacokinetic Parameters for T4 (Pharmacokinetic Population)

Parameter	Treatment	N	Geo-LSMean	Ratio		Intra-CV (%)
				(Treatments) (%)	95% CI of Ratio	
AUC _{0-72,adj} (hr*ng/mL)	B	37	2222.979	99.3	91.8 - 107.5	17.1
	A	37	2237.745			
	C	37	2329.393	104.1	96.2 - 112.6	17.1
	A	37	2237.745			
	C	37	2329.393	104.8	96.8 - 113.4	17.1
	B	37	2222.979			
C _{max,adj} (ng/mL)	B	37	62.1190	103.8	96.7 - 111.5	15.5
	A	37	59.8409			
	C	37	61.7588	103.2	96.1 - 110.8	15.5
	A	37	59.8409			
	C	37	61.7588	99.4	92.6 - 106.8	15.5
	B	37	62.1190			

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; Geo-LSMean: Geometric Least Square Mean;
 N: Number of subjects included in the analysis. T4: Tetraiodothyronine;
 Subjects 1017,1033,1048,1079 and 1090 were excluded from the PK Population.
 Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;
 Source: Appendix 16.1.9.1

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.3.1.sas

18DEC2014 00:14

Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002Page 1 of 2
Confidential

Table 15.4.3.2 Summary of ANOVA of Secondary Pharmacokinetic Parameters for T4 and T3 (Pharmacokinetic Population)

Analyte	Parameter	Treatment	N	Geo-LSMean	Ratio	90% CI of Ratio	Intra-CV (%)
					(Treatments) (%)		
T4	AUC ₀₋₄₈ , adj (hr*ng/mL)	B	37	1629.858	100.1	93.8 - 106.8	16.8
		A	37	1628.390			
		C	37	1707.930	104.9	98.3 - 111.9	16.8
		A	37	1628.390			
		C	37	1707.930	104.8	98.2 - 111.8	16.8
		B	37	1629.858			

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; Geo-LSMean: Geometric Least Square Mean;
 N: Number of subjects included in the analysis. T3: Triiodothyronine. T4 : Thyroxine
 Subjects 1017,1033,1048,1079 and 1090 were excluded from the PK Population.;
 Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
 Treatment C: 3 tablets of 200 µg of levothyroxine;
 Source: Appendix 16.1.9.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
 15.4.3.2.sas

18DEC2014 00:14



Levothyroxine
EMR 200125-002

Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Merck Serono
EMR 200125-002
Table 15.4.3.2 Summary of ANOVA of Secondary Pharmacokinetic Parameters for T4 and T3 (Pharmacokinetic Population)

Page 2 of 2
Confidential

Analyte	Parameter	Treatment	N	Geo-LSMean	Ratio (Treatments) (%)	90% CI of Ratio	Intra-CV (%)
T3	AUC ₀₋₄₈ (hr*ng/mL)	B	37	40.2952	99.5	96.7 - 102.2	7.1
		A	37	40.5169			
		C	37	39.8096	98.3	95.6 - 101.0	7.1
		A	37	40.5169			
		C	37	39.8096	98.8	96.1 - 101.6	7.1
		B	37	40.2952			
	C _{max} (ng/mL)	B	37	1.0269	98.4	94.7 - 102.3	10.0
		A	37	1.0434			
		C	37	1.0373	99.4	95.7 - 103.3	10.0
		A	37	1.0434			
		C	37	1.0373	101.0	97.2 - 105.0	10.0
		B	37	1.0269			

CI: Confidence Interval; CV%: Coefficient of Variation Percentage; Geo-LSMean: Geometric Least Square Mean;
N: Number of subjects included in the analysis. T3: Triiodothyronine. T4 : Thyroxine
Subjects 1017,1033,1048,1079 and 1090 were excluded from the PK Population.;
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;
Source: Appendix 16.1.9.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Tables/Table
15.4.3.2.sas

18DEC2014 00:14



Levothyroxine Dosage Form Proportionality of Levothyroxine New Formulations (50 µg,
100 µg, and 200 µg Tablets) in Fasted State
EMR 200125-002

15.4.2 Graphs


- Figure 15.4.2.1 Concentration-Time Profiles: Arithmetic Mean (\pm SD) versus Scheduled Sampling Time in Linear Scale (for Total T4 Values)(Pharmacokinetic Population)
- Figure 15.4.2.2 Concentration-Time Profiles: Arithmetic Mean versus Scheduled Sampling Time in Semi-Logarithmic Scale (for Total T4 Values)(Pharmacokinetic Population)
- Figure 15.4.2.3 Concentration-Time Profiles: Arithmetic Mean (\pm SD) versus Scheduled Sampling Time in Linear Scale (for Total T3 Values)(Pharmacokinetic Population)
- Figure 15.4.2.4 Concentration-Time Profiles: Arithmetic Mean versus Scheduled Sampling Time in Semi-Logarithmic Scale (For Total T3 Values)(Pharmacokinetic Population)
- Figure 15.4.2.5 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (Spaghetti Plots) (for Total T4 Values)(Pharmacokinetic Population)
- Figure 15.4.2.6 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (Spaghetti Plots) (for Total T4 Values)(Pharmacokinetic Population)
- Figure 15.4.2.7 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (Spaghetti Plots) (for Total T3 Values)(Pharmacokinetic Population)
- Figure 15.4.2.8 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (Spaghetti Plots)(for Total T3 Values)(Pharmacokinetic Population)
- Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)
- Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T4 Values) (Safety Population)
- Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Levothyroxine Dosage Form Proportionality of Levothyroxine New Formulations (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

EMR 200125-002

- Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 Values) (Safety Population)
- Figure 15.4.3.1.1 Boxplot: C_{\max} and AUC_{0-72} for Total T4 (Pharmacokinetic Population)
- Figure 15.4.3.1.2 Boxplot: Baseline-Adjusted C_{\max} and Baseline-Adjusted AUC_{0-72} for Total T4 (Pharmacokinetic Population)
- Figure 15.4.3.1.3 Boxplot: Baseline-Adjusted AUC_{0-48} for Total T4 (Pharmacokinetic Population)
- Figure 15.4.3.1.4 Boxplot: C_{\max} and AUC_{0-48} for Total T3 (Pharmacokinetic Population)

Figure 15.4.2.1 Concentration-Time Profiles: Arithmetic Mean (± SD) versus Scheduled Sampling Time in Linear Scale (for Total T4 Values) (Pharmacokinetic Population)




Subjects: ... were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.1

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.1.sas

10DEC2014 00:20

Figure 15.4.2.2 Concentration-Time Profiles: Arithmetic Mean versus Scheduled Sampling Time in Semi-Logarithmic Scale (for Total T4 Values) (Pharmacokinetic Population)




Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.1

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.2.sas

10DEC2014 00:20

Figure 15.4.2.3 Concentration-Time Profiles: Arithmetic Mean (± SD) versus Scheduled Sampling Time in Linear Scale (for Total T3 Values) (Pharmacokinetic Population)



Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.3

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.3.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002


Dosage Form Proportions
State EMR200125-002 Page 470 of 658

ions (50 µg, 100 µg, and 200 µg Tablets) in Fasted

Merck Serono
EMR 200125-002

Page 1 of 1
Confidential

Figure 15.4.2.4 Concentration-Time Profiles: Arithmetic Mean versus Scheduled Sampling Time in Semi-Logarithmic Scale (For Total T3 Values) (Pharmacokinetic Population)



Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.1


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.4.sas

10DEC2014 00:20



Figure 15.4.2.5 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (Spaghetti Plots) (for Total T4 Values) (Pharmacokinetic Population)

Treatment: Treatment A



Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.1


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.5.sas

10DEC2014 00:20



Figure 15.4.2.5 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (Spaghetti Plots) (for Total T4 Values) (Pharmacokinetic Population)

Treatment: Treatment B



Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.1

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.5.sas


10DEC2014 00:20

Merck Serono
EMR 200125-002

Page 3 of 3
Confidential

Figure 15.4.2.5 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (Spaghetti Plots) (for Total T4 Values) (Pharmacokinetic Population)

Treatment: Treatment C




Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.1

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.5.sas

10DEC2014 00:20

Figure 15.4.2.6 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (Spaghetti Plots) (For Total T4 Values) (Pharmacokinetic Population)

Treatment: Treatment A



Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.1

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.6.sas

10DEC2014 00:20

Levothyroxine
EMR 200125-002

Dosage Form Proportion: ...
State EMR200125-002 Page 475 of 658


ions (50 µg, 100 µg, and 200 µg Tablets) in Fasted

Merck Serono
EMR 200125-002

Page 2 of 3
Confidential

Figure 15.4.2.6 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (Spaghetti Plots) (For Total T4 Values) (Pharmacokinetic Population)

Treatment: Treatment B



Subjects ... were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.1


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.6.sas

10DEC2014 00:20



Figure 15.4.2.6 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (Spaghetti Plots) (For Total T4 Values) (Pharmacokinetic Population)

Treatment: Treatment C




Subjects ... were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.1

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.6.sas

10DEC2014 00:20

Figure 15.4.2.7 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (Spaghetti Plots) (for Total T3 Values) (Pharmacokinetic Population)

Treatment: Treatment A



Subjects () were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.3


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.7.sas

10DEC2014 00:20

Merck Serono
EMR 200125-002

Figure 15.4.2.7 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (Spaghetti Plots) (for Total T3 Values) (Pharmacokinetic Population)

Treatment: Treatment B



Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.3

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.7.sas


10DEC2014 00:20



Merck Serono
EMR 200125-002

Figure 15.4.2.7 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (Spaghetti Plots) (for Total T3 Values) (Pharmacokinetic Population)

Treatment: Treatment C



Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.3

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.7.sas

10DEC2014 00:20



Levothyroxine
EMR 200125-002

Dosage Form Proportions (50 µg, 100 µg, and 200 µg Tablets) in Fasted State
EMR200125-002 Page 480 of 658

ions (50 µg, 100 µg, and 200 µg Tablets) in Fasted


Merck Serono
EMR 200125-002

Page 1 of 3

Confidential

Figure 15.4.2.8 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (Spaghetti Plots) (for Total T3 Values) (Pharmacokinetic Population)

Treatment: Treatment A



Subjects [redacted] were excluded from the PK Population.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;

Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Table 15.4.1.1.3

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.8.sas


10DEC2014 00:20

Merck Serono
EMR 200125-002

Page 2 of 3
Confidential

Figure 15.4.2.8 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (Spaghetti Plots) (for Total T3 Values) (Pharmacokinetic Population)

Treatment: Treatment B



Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.3


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.8.sas

10DEC2014 00:20



Figure 15.4.2.8 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (Spaghetti Plots) (for Total T3 Values) (Pharmacokinetic Population)

Treatment: Treatment C




Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: Table 15.4.1.1.3

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.8.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)
(Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: _____



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: :




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2


/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure .
15.4.2.9.sas

10DEC2014 00:20



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: [REDACTED]



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.2

/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.9.sas

10DEC2014 00:20